Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HHS vs DLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DLX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–4 Matrix Metrics)

DLX Overall Winner 6-Pillar Tally: HHS 0 – 5 DLX (1 Tie) Matrix Metrics: HHS 4 – 6 DLX

As of Nov 16, 2026, Deluxe Corporation (DLX) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas DLX carries 31.4/100 (SELL) at $27.05 (6.5x Forward P/E, 12.8% operating margin).

  • Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. DLX 31.4/100 SELL), DLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.8% vs. -3.2% operating margin) and revenue trajectory (+2.5% vs. -1.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HHS vs DLX
HHS US Equity
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.84
-4.24% 1D
Market Cap $30.0M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26
DLX NYSE Head-to-Head Winner
Deluxe Corporation
Blankbooks, Looseleaf Binders & Bookbindg & Relatd Work
$27.05
+1.01% 1D
Market Cap $1.2B
TTM Revenue $2.13B
Forward P/E 6.5x
Beta / 30D Vol -0.45β · 75% Vol
Unified Composite Score
31.4 / 100 SELL
Tech 50.0 Fund 28.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 66
RSI-14: 65.8 · SMA20: $24.52 · SMA50: $23.80

6-Pillar Scorecard Institutional Category Breakdown (HHS 0 – 5 DLX)

Columns: Metric · HHS · DLX
1. Valuation Multiples DLX
Forward P/E 14.3x 6.5x
Trailing P/E 14.3x 15.5x
PEG Ratio 1.19x 0.53x
EV / Revenue 0.3x 0.6x
2. Growth & Scale DLX
Revenue Growth (YoY) -1.7% +2.5%
Earnings Growth (YoY) -90.3% -62.2%
TTM Revenue (USD) $155M $2.13B
Market Cap $30.0M $1.2B
3. Profitability & Quality DLX
Gross Margin 16.1% 52.1%
Operating Margin -3.2% 12.8%
Net Profit Margin -3.7% 3.8%
Return on Equity (ROE) -30.4% 11.6%
4. Balance Sheet & Cash Flow DLX
Cash Generation (TTM) -$4.5M $428M EBITDA
Cash Flow Margin -2.9% 20.1% EBITDA Mgn
Net Cash / Leverage $17M Net Debt (1.10x D/E) $15.63 Book/Sh · 11.6% ROE
Dividend Yield None (0.00%) 4.52%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 24.9% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat DLX
OpEx & R&D Intensity 19.3% of Rev ($30M) 39.3% of Rev ($836M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Conglomerates Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HHS (4) vs DLX (6)
Institutional Metric HHS DLX Criterion Row Edge
Market Capitalization
Scale
$30.0M $1.2B Larger Scale DLX
Trailing P/E Ratio
Valuation
14.3x 15.5x Lower Multiple HHS
Forward P/E Ratio
Valuation
14.3x 6.5x Lower Multiple DLX
Revenue Growth (YoY)
Growth
-1.7% +2.5% Higher Growth DLX
Operating Margin (TTM)
Profitability
-3.2% 12.8% Higher Margin DLX
Net Profit Margin
Profitability
-3.7% 3.8% Higher Margin DLX
Return on Equity (ROE)
Capital Efficiency
-30.4% 11.6% Higher ROE DLX
52-Week Range Position
Momentum
69% ($2–$5) 63% ($19–$32) Stronger Trend HHS
Beta / 30D Volatility
Risk Regime
0.49β · 46% Vol -0.45β · 75% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
61.8 / 100 (BUY) 31.4 / 100 (SELL) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
$155M $2.13B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.1% 52.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.19x PEG · 0.3x EV/Rev 0.53x PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.5M ($17M Net Debt (1.10x D/E)) $428M EBITDA ($15.63 Book/Sh · 11.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DLX +27.19 pp
HHS: -10.49% · DLX: +16.7%
3M Horizon DLX +19.75 pp
HHS: -3.76% · DLX: +15.99%
6M Horizon HHS +34.4 pp
HHS: +36.17% · DLX: +1.77%
1Y Horizon HHS +2.4 pp
HHS: +34.74% · DLX: +32.34%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs DLX. Trailing 12-month operating profitability (HHS -3.2% vs DLX 12.8%) and valuation multiples (HHS 14.3x vs DLX 6.5x Forward P/E) are benchmarked directly in Pillar 4 below.

HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x
DLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.13B
Gross Margin52.1%
Op. Margin12.8%
ROE / Fwd P/E11.6% · 6.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.9%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published
DLX Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $1.2B market capitalization and 12.8% operating margin.
OpEx & R&D Reinvestment 39.3% of Rev ($836M)
90D Engineering Disclosures 0 Published

Investor FAQ HHS vs DLX Key Questions & Quantitative Answers

As of Nov 16, 2026, Deluxe Corporation (DLX) is the stronger overall head-to-head candidate over Harte Hanks, Inc. (HHS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HHS carries a Unified Composite Score of 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin), whereas DLX carries 31.4/100 (SELL) at $27.05 (6.5x Forward P/E, 12.8% operating margin). Composite vs. Pillar Nuance: While HHS currently prints a higher short-term Unified Composite Score (61.8/100 BUY vs. DLX 31.4/100 SELL), DLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.8% vs. -3.2% operating margin) and revenue trajectory (+2.5% vs. -1.7% YoY).

DLX leads the Growth & Scale pillar: HHS posts -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin), compared with DLX at +2.5% YoY revenue growth and -62.2% YoY earnings growth on $2.13B TTM revenue (52.1% gross margin, 12.8% operating margin). On trailing 12-month operating scale, HHS generates $155M in USD-normalized revenue versus $2.13B for DLX. In operating R&D and SG&A reinvestment, HHS deploys 19.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus 39.3% of Rev ($836M) (0 disclosures) for DLX.

DLX screens cheaper on headline valuation multiples. HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin), whereas DLX trades at 6.5x Forward P/E, 15.5x Trailing P/E, 0.53x PEG, and 0.6x EV/Revenue (20.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HHS (-30.4% ROE) versus DLX (11.6% ROE) capital efficiency.

In options market volatility and institutional positioning, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk). By comparison, DLX carries 24.9% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.45β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.